We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions.
- Authors
Albrecht, J. Mark; Cooper, Benjamin R.; Waller, Jacquelyn D.; Presley, Colby L.; Pulsipher, Kayd J.; Rundle, Chandler W.; Dellavalle, Robert P.
- Abstract
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvirritonivir and commonly-used medications within dermatology.
- Subjects
COVID-19 pandemic; DRUG side effects; DERMATOLOGISTS; DERMATOLOGY; DRUG tablets
- Publication
Dermatology Online Journal, 2023, Vol 29, Issue 1, p1
- ISSN
1087-2108
- Publication type
Article
- DOI
10.5070/D329160209